Adjuvant treatment with a symbiotic in patients with inflammatory non-allergic rhinitis.
J Biol Regul Homeost Agents
; 31(1): 201-206, 2017.
Article
en En
| MEDLINE
| ID: mdl-28337893
ABSTRACT
Inflammatory non-allergic rhinitis (INAR) is characterized by the presence of an inflammatory infiltrate and a non-IgE-mediated pathogenesis. This retrospective, controlled, multicentre study investigated whether a symbiotic, containing Lactobacillus acidophilus NCFM, Bifidobacterium lactis, and fructo-oligosaccharides (Pollagen®, Allergy Therapeutics, Italy), prescribed as adjunctive therapy to a standard pharmacological treatment, was able to reduce symptom severity, endoscopic features, and nasal cytology in 93 patients (49 males and 44 females, mean age 36.3±7.1 years) with INAR. The patients were treated with nasal corticosteroid, oral antihistamine, and isotonic saline. At randomization, 52 patients were treated also with symbiotic as adjunctive therapy, whereas the remaining 41 patients served as controls. Treatment lasted for 4 weeks. Patients were visited at baseline, after treatment, and after 4-week follow-up. Adjunctive symbiotic treatment significantly reduced the percentages of patients with symptoms and endoscopic signs, and diminished inflammatory cells. In conclusion, the present study demonstrates that a symbiotic was able, as adjuvant treatment, to significantly improve symptoms, endoscopic feature, and cytology in patients with INAR, and its effect may be long lasting.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Rinitis
/
Adyuvantes Inmunológicos
/
Adyuvantes Farmacéuticos
/
Probióticos
/
Bifidobacterium animalis
/
Lactobacillus acidophilus
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Idioma:
En
Revista:
J Biol Regul Homeost Agents
Asunto de la revista:
BIOLOGIA
/
BIOQUIMICA
Año:
2017
Tipo del documento:
Article